KTRA Profile
Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative anti-cancer therapies. The company specializes in advancing therapies for cancer patients with unmet medical needs. Its core focus lies in two late-stage, Phase III-ready therapeutic candidates: VAL-083 and REM-001. VAL-083 is a DNA-targeting agent designed to treat drug-resistant solid tumors. This includes glioblastoma multiforme (GBM), a highly aggressive brain tumor, as well as other solid tumors such as ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG). VAL-083's unique mechanism of action aims to overcome resistance seen with conventional treatments, potentially offering new hope for patients with these challenging cancers.
REM-001 represents Kintara's late-stage photodynamic therapy, developed for the treatment of various skin and localized cancers. This includes cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. REM-001 utilizes light-activated technology to selectively target and destroy cancerous cells, providing a targeted approach to therapy that minimizes damage to surrounding healthy tissue. This innovative treatment modality aims to address significant gaps in current cancer care and improve outcomes for patients with these conditions.
The company has strategically partnered with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to enhance the global reach of VAL-083. This collaboration focuses on the manufacturing and commercialization of VAL-083 in China, expanding its market presence and accelerating its availability to patients in one of the world's largest pharmaceutical markets. Such strategic alliances are crucial for Kintara as it works to advance its therapies through international markets and regulatory pathways.
Originally known as DelMar Pharmaceuticals, Inc., Kintara Therapeutics rebranded in August 2020 to reflect its evolving mission and focus on advancing its pipeline of anti-cancer therapies. Incorporated in 2009 and headquartered in San Diego, California, Kintara is committed to addressing critical needs in oncology and improving patient outcomes through its innovative approach to cancer treatment.
|
